Myriad's EndoPredict offers better prediction of breast cancer recurrence, analysis shows


Large National Payer Expands Coverage Policy to Include EndoPredict for Guiding Extended Hormone Therapy for Patients with ER+ Breast Cancer Myriad Genetics, Inc. today announced that a comparative analysis of commercially available prognostic breast cancer tests in patients with early-stage breast cancer has been published in JAMA Oncology . A key finding is that Myriad's EndoPredict significantly outperformed Oncotype DX Recurrence Score at predicting the risk of disease recurrence in patients with early-stage breast cancer.



from Biotech News